What's Happening?
Panome Bio, a St. Louis-based multi-omics contract research organization, has announced a strategic partnership with Audubon Bioscience, a global biospecimen provider. This collaboration aims to provide cancer researchers with a streamlined process from
the acquisition of ethically sourced formalin-fixed paraffin-embedded (FFPE) tissue to comprehensive metabolomics analysis. The partnership, unveiled at the AACR Annual Meeting 2026 in San Diego, leverages Panome Bio's TissueBridge™ FFPE Metabolomics platform, which integrates into existing pathology workflows. Audubon Bioscience contributes its extensive biobanking infrastructure, ensuring quality-controlled FFPE tissue procurement. This partnership is set to accelerate biomarker discovery and the identification of novel drug targets by providing a reliable path from tissue acquisition to metabolic profiling.
Why It's Important?
The collaboration between Panome Bio and Audubon Bioscience addresses a significant bottleneck in cancer research by facilitating access to clinical archives for metabolomics analysis. This development is crucial as it allows researchers to utilize decades of collected FFPE tissue, which was previously inaccessible for such detailed metabolic interrogation. By enhancing the ability to conduct retrospective cohort studies and biomarker discovery, this partnership could lead to breakthroughs in cancer diagnostics and treatment. The integration of metabolomics into cancer research provides a new dimension of biological insight, potentially leading to the development of more effective therapies and improving patient outcomes.
What's Next?
Researchers interested in the new capabilities offered by this partnership can learn more at the AACR Annual Meeting 2026, where Panome Bio and Audubon Bioscience are exhibiting. The partnership is expected to attract interest from pharmaceutical and biotechnology companies seeking to leverage the enhanced metabolomics capabilities for drug development. As the collaboration progresses, it may lead to further innovations in cancer research methodologies and potentially expand to include other disease areas.
